Frank Glavin

Frank is the Chief Executive Officer of Meissa Vaccines. He was previously CEO of Orphan Technologies, which advanced two rare disease assets from the lab to the clinic culminating in a sale to Travere Therapeutics (Nasdaq: TVTX). In addition, he was the Head of Neovii Biotech North America, where he was responsible for clinical development, regulatory approval, and commercialization of the US Oncology and Hematology/Transplant portfolio. Frank has more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. He has a B.S. in human physiology from Boston University and M.B.A. from Cornell University's Samuel Curtis Johnson Graduate School of Management.